BDX vs CGON: fair value comparison
Becton, Dickinson and Company and CG Oncology, Inc. · Updated 2026-10-19
CGON has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BDX currently ranks higher by quality score.
| BDX | CGON | |
|---|---|---|
| Verdict | Undervalued | No estimate yet |
| Last price | $183.75 | $59.85 |
| 12-month range | $138.67–$193.76 | $37.37–$80.68 |
| Rank by discount to fair value | #38 of 108 Healthcare | — |
| Rank by quality score | #152 of 301 Healthcare | #154 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BDX fair value analysis · CGON fair value analysis